New to The Street Signs National Media Agreement with NRx Pharmaceuticals for 12-Part Broadcast Series Across TV, Digital, and Outdoor Platforms
The partnership will feature monthly televised interviews with NRx CEO Dr. Jonathan Javitt, providing updates from the front lines of biotech innovation. As part of the comprehensive campaign, New to The Street will also produce earned media placements on ABC, NBC, and CBS affiliates, a full suite of nationally aired TV commercials, and premium outdoor billboard exposure in Times Square and throughout the NYC Financial District.
'Our mission has always been to save lives with science,' said Jonathan Javitt, MD, MPH, Founder and CEO of NRx Pharmaceuticals. 'Partnering with New to The Street enables us to share the life-saving potential of NRX-101 and our broader pipeline with a national audience, at a pivotal moment in our regulatory and commercial path.'
'We are proud to bring NRX's critical work to our global audience,' said Vince Caruso, Co-Founder and CEO of New to The Street. 'This series will spotlight a company on the front lines of neuroscience and public health, and exemplifies our commitment to covering stories that matter-with scale, credibility, and impact.'
The series begins airing later this month on Fox Business and Bloomberg Television as sponsored programming, reaching more than 245 million homes weekly across the U.S. and Middle East. Episodes will also stream on New to The Street's YouTube channel, which now exceeds 2.5 million subscribers, and be supported by billboard takeovers in Times Square and full media amplification through the NewsOut™ and AccreditedEvents.com platforms.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for treating central nervous system disorders. Its lead investigational drug, NRX-101, has been granted FDA Breakthrough Therapy and Fast Track Designation for suicidal bipolar depression. The company is also pursuing accelerated approval for preservative-free IV ketamine (NRX-100) and advancing additional treatments for PTSD, chronic pain, and UTIs. Learn more at www.nrxpharma.com.
About New to The Street
New to The Street is a leading branded content TV series that features innovative public and private companies on national television, including Fox Business and Bloomberg Television. With more than 2.52 million YouTube subscribers, a reach of 245 million TV households, and a powerful outdoor media footprint, the platform offers unmatched exposure across digital, television, and out-of-home channels. Learn more at www.NewToTheStreet.com.
SOURCE: New To The Street
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Wells Fargo Raises PT on Health Catalyst, Inc. (HCAT); Maintains ‘Buy' Rating
Health Catalyst, Inc. (NASDAQ:HCAT), having a share price under $10, strong hedge fund interest, and a low price-to-earnings ratio, ranks among the . A data center operator working on a rack of servers, emphasizing the company's cloud services. On July 1, 2025, Wells Fargo set its price target at $10 for Health Catalyst, Inc. (NASDAQ:HCAT), maintaining a 'Buy' rating. HCAT's shares are currently trading at around $4, implying a significant upside as per the analyst. The analyst believes that Health Catalyst, Inc. (NASDAQ:HCAT) is valued much lower than its peers, which sets the company up for future growth through consistent performance. The firm expects positive growth in the company's bookings in the upcoming Q2, which is likely to boost investor sentiment. Meanwhile, the company's strong revenue visibility for 2025 is noted, along with an anticipated acceleration in its DOS client growth. Looking ahead, the analyst expects the company to improve its dollar-based retention rate, enhancing its customer loyalty and revenue base. Legislative uncertainties, on the other hand, are expected to be short-term concerns with minimal long-term impact. Lastly, the company's EBITDA growth was also highlighted as a key reason for the optimistic outlook. With Health Catalyst Ignite, a cloud-based data and analytics platform, Health Catalyst, Inc. (NASDAQ:HCAT) serves healthcare entities, enhancing clinical, financial, and operational results. It is included in our list of the best cloud stocks. While we acknowledge the potential of HCAT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 14 Cheap Transportation Stocks to Buy According to Analysts and 11 Best Mineral Stocks to Buy According to Hedge Funds. Disclosure: None.
Yahoo
24 minutes ago
- Yahoo
Wolfe Research Initiates Coverage on Harmonic Inc. (HLIT) with ‘Underperform' Rating
Harmonic Inc. (NASDAQ:HLIT), having a share price under $10, strong hedge fund interest, and a low price-to-earnings ratio, ranks among the . On July 8, 2025, Wolfe Research initiated coverage on Harmonic Inc. (NASDAQ:HLIT) with a price target of $7 and an 'Underperform' rating. This comes ahead of the company's earnings release for Q2, which is scheduled for July 28, 2025. The analyst's price target implies a downtick from the company's current share price of $9.10. However, several other analysts, such as Rosenblatt, Needham, and Barclays, have recently given bullish ratings on the company. Despite a sluggish outlook, analysts project strong growth in 2025, where they project a revenue growth of 30.29%, taking the total expected revenue from $645.2 million in 2025 to $840.6 million in 2026. This growth is driven by Harmonic Inc. (NASDAQ:HLIT)'s strategic partnerships and technological innovation, as its recent deals with Vectra and Cignal TV demonstrate its growing global footprint in the realm of broadband and video streaming. Furthermore, its innovative PTP-less DAA deployment and cloud-native VOS360 platform are expected to bolster its competitive edge. While there have been delays in the short-term rollouts, management remains optimistic. Looking ahead, the analysts expect an improved second half of 2025 and a strong 2026 performance, driven by strong demand amid the company's collaboration with CUJO AI that will enhance broadband connectivity. With the help of its software and SaaS platforms, Harmonic Inc. (NASDAQ:HLIT) offers cloud-based broadband and video solutions, serving operators and media companies by delivering high-speed internet and advanced streaming services. It is included in our list of the best cloud stocks. While we acknowledge the potential of HLIT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 14 Cheap Transportation Stocks to Buy According to Analysts and 11 Best Mineral Stocks to Buy According to Hedge Funds. Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
24 minutes ago
- Yahoo
TTEC Holdings, Inc. (TTEC) Experiences Strong Momentum Following First Quarter
TTEC Holdings, Inc. (NASDAQ:TTEC), having a share price under $10, strong hedge fund interest, and a low price-to-earnings ratio, ranks among the . A network of interconnected data points representing cloud-based software solutions. TTEC Holdings, Inc. (NASDAQ:TTEC) is experiencing a solid stock momentum with 42.30% and 41.93% share price gains over the past three months and six months, respectively. This is driven by growing investor interest in the company's customer engagement. Further reinforcing its momentum is its past month's gain of 12.84%, reflecting growing confidence in the company. Along with this positive momentum, the company's stock remains attractively priced, valued at just 0.11 times its sales. This momentum follows the company's Q1 results, announced on May 8, 2025. TTEC Holdings, Inc. (NASDAQ:TTEC) remained resilient with its strong operational performance, reporting a 10.6% adjusted EBITDA margin and a net income of $3.2 million, a significant improvement from the prior year. This comes despite a 7.4% revenue decrease. Furthermore, TTEC generated a positive cash flow of $21.6 million, demonstrating its strong financial health. Although global economic uncertainties remain, TTEC Holdings, Inc. (NASDAQ:TTEC) remains optimistic about its 2025 outlook, anticipating continued growth. Enhancing customer and employee experiences across all channels, TTEC Holdings, Inc. (NASDAQ:TTEC) delivers comprehensive cloud-based solutions including CX strategy, analytics, AI automation, omnichannel orchestration, and contact center software. It is included in our list of the best cloud stocks. While we acknowledge the potential of TTEC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 14 Cheap Transportation Stocks to Buy According to Analysts and 11 Best Mineral Stocks to Buy According to Hedge Funds. Disclosure: None.
